TLC399

Taiwan Liposome Company · Phase 1 active Small molecule

At a glance

Generic name	TLC399
Also known as	TLC399 (BioSeizer)
Sponsor	Taiwan Liposome Company
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO) (PHASE2)
Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TLC399 CI brief — competitive landscape report
TLC399 updates RSS · CI watch RSS
Taiwan Liposome Company portfolio CI